# **PRODUCT** INFORMATION



## Faldaprevir-d<sub>6</sub>

Item No. 31480

CAS Registry No.: Formal Name:	2750534-88-2 (1R,2S)-N-[(cyclopentyloxy)carbonyl]- 3-methyl-L-valyl-(4R)-4-[[8-bromo-7- methoxy-2-[2-[(2-methyl-d <sub>3</sub> -1-oxopropyl) amino-3,3,3-d <sub>3</sub> ]-4-thiazolyl]-4-quinolinyl]	
	oxy]-L-prolyl-1-amino-2-ethenyl-	Br
	cyclopropanecarboxylic acid	N
Synonym:	BI-201335-d <sub>6</sub>	
MF:	C <sub>40</sub> H <sub>43</sub> BrD <sub>6</sub> N <sub>6</sub> O <sub>9</sub> S	
FW:	875.9	
Chemical Purity:	≥98% (Faldaprevir)	
Deuterium		ОН
Incorporation:	≥99% deuterated forms (d <sub>1</sub> -d <sub>6</sub> ); ≤1% d <sub>0</sub>	
Supplied as:	A solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

#### Laboratory Procedures

Faldaprevir-d<sub>4</sub> is intended for use as an internal standard for the quantification of faldaprevir by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Faldaprevir-d<sub>6</sub> is supplied as a solid. A stock solution may be made by dissolving the faldaprevir-d<sub>6</sub> in the solvent of choice, which should be purged with an inert gas. Faldaprevir-d<sub>4</sub> is soluble in the organic solvent DMSO.

#### Description

Faldaprevir is an inhibitor of hepatitis C virus (HCV) non-structural protease 3/4A (NS3/4A; IC<sub>50</sub> = 3 nM for the HCV genotype 1b enzyme).<sup>1</sup> It inhibits genotype 1a and 1b HCV RNA replication in replicon assays  $(EC_{50}s = 6.5 \text{ and } 3.1 \text{ nM}, \text{ respectively}).^2$ 

#### References

- 1. Llinàs-Brunet, M., Bailey, M.D., Goudreau, N., et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J. Med. Chem. 53(17), 6466-6476 (2010).
- 2. White, P.W., Llinàs-Brunet, M., Amad, M., et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother. 54(1), 4611-4618 (2010).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/26/2023

### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM